£40.6M
The Boston investor backs the clinical stage biotechnology firm to advance its immune-resetting therapies.
"We have two clinical stage drug product candidates, '1805 and '1104, that have demonstrated impressive efficacy and safety data in phase 2a clinical studies on Rheumatoid Arthritis and Allergic Disease respectively and we are delighted to have Morningside as a partner to advance our programs,"
